Liji Shen

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Johann S. de Bono, Stéphane Oudard, Mustafa Özgüroğlu et al. · The Lancet · 2010 · 3.3K citations

Urology, Medicine, Pharmacology +7

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA

Stéphane Oudard, Karim Fizazi, Lisa Sengeløv et al. · Journal of Clinical Oncology · 2017 · 350 citations

Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use

David Lorente, Joaquı́n Mateo, Arnoud J. Templeton et al. · Annals of Oncology · 2014 · 188 citations · Full text

Urology, Baseline Neutrophil–lymphocyte Ratio, Medicine +7

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Amit Bahl, Stéphane Oudard, Bertrand Tombal et al. · Annals of Oncology · 2013 · 170 citations · Full text

Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy

Susan Halabi, Chenyu Lin, Eric J. Small et al. · JNCI Journal of the National Cancer Institute · 2013 · 158 citations · Full text